Disposition of 100000 shares by Niklason Laura E of Humacyte at 1.19 subject to Rule 16b-3

HUMA Stock  USD 5.50  0.21  3.97%   
About 54% of Humacyte's investor base is interested to short. The analysis of the overall investor sentiment regarding Humacyte suggests that many traders are impartial. The current market sentiment, together with Humacyte's historical and current headlines, can help investors time the market. In addition, many technical investors use Humacyte stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Humacyte Director, 10 Percent Owner, Officer: President, Ceo And Director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at gurufocus.com
Gurufocus Stories at Macroaxis
  

Humacyte Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Humacyte can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Humacyte Fundamental Analysis

We analyze Humacyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Humacyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Humacyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Debt To Equity

Debt To Equity Comparative Analysis

Humacyte is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

Humacyte Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Humacyte stock to make a market-neutral strategy. Peer analysis of Humacyte could also be used in its relative valuation, which is a method of valuing Humacyte by comparing valuation metrics with similar companies.

Peers

Humacyte Related Equities

QSIQuantumSi   67.44   
0%
100.0%
MNOVMediciNova   6.15   
0%
9.0%
LYRALyra Therapeutics   5.56   
0%
8.0%
HCWBHCW Biologics   5.00   
0%
7.0%
SEERSeer   3.20   
0%
4.0%
LRMRLarimar Therapeutics   1.00   
1.0%
0%
MIRMMirum Pharmaceuticals   1.12   
1.0%
0%
GPCRStructure Therapeutics   1.69   
2.0%
0%
VRDNViridian Therapeutics   1.92   
2.0%
0%
CYTKCytokinetics   2.43   
3.0%
0%
KALVKalvista Pharmaceuticals   3.40   
5.0%
0%
IMCRImmunocore Holdings   3.44   
5.0%
0%
KURAKura Oncology   3.45   
5.0%
0%
CRNXCrinetics Pharmaceuticals   3.84   
5.0%
0%
NRIXNurix Therapeutics   4.11   
6.0%
0%

Complementary Tools for Humacyte Stock analysis

When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Fundamental Analysis
View fundamental data based on most recent published financial statements
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated